Malaria, a parasitic disease caused by Plasmodium parasites, poses a significant threat to public health and the global economy, particularly in sub-Saharan Africa. Nigeria, with its high malaria burden, has been at the forefront of implementing various interventions to control the disease. Among these, the R21/Matrix-M malaria vaccine has shown promising results in reducing malaria incidents in children aged 3-36 months. However, the success of any vaccine program relies on public awareness, acceptance, and affordability.
This study aimed to assess the awareness, acceptability, and willingness to pay (WTP) for the R21/Matrix-M vaccine among pregnant women and nursing mothers in Enugu State, Nigeria. The findings revealed a limited awareness of the vaccine, with most participants being unaware of its existence. Despite this, a high percentage of participants expressed a willingness to accept and vaccinate their children with the vaccine, and many were also willing to pay for it.
The study's results provide valuable insights into the potential market value and financial viability of introducing the malaria vaccine in Nigeria. By understanding the factors influencing WTP, policymakers can design equitable and sustainable implementation strategies.
The findings also highlight the importance of addressing vaccine hesitancy, which has been a significant concern in Nigeria, especially during the COVID-19 vaccination rollout. Public health awareness campaigns and education on vaccine importance can help overcome this barrier.
Furthermore, the study's demographic focus on pregnant women and nursing mothers is crucial, as they play a central role in healthcare decision-making for children under five, one of the most vulnerable groups affected by malaria.
In conclusion, while there is a need for increased awareness of the R21/Matrix-M vaccine, the study's findings suggest that with proper education and communication, the vaccine could have high acceptance and coverage, ultimately contributing to the reduction of malaria burden in Nigeria and supporting global efforts to improve public health outcomes.
